Related Experiment Video
Updated: Jun 28, 2026

12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Safety and outcomes of CD19 CAR-T cell therapy in splenectomized patients with B-cell lymphomas
Niveen Shibli1, Sigrun Einarsdottir2, Teng Fei3
1Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Transplantation and Cellular Therapy
|June 26, 2026
Summary
No abstract available in PubMed .
Keywords:
Chimeric antigen receptor T (CAR-T) cell therapyrelapsed or refractory (R/R) B-cell malignanciessplenectomized patientsMore Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022